Demographic pattern of incidenceof breast carcinoma by subtype

- A comparative study

Guvera vasireddy, Assistant professor

Dr. Triveni Bhopal, Professor

MNJ institute of Oncology / OMC

Dr. Ezhil Arasi. N, Professor and HOD

Department of pathology ,

Osmania Medical College, koti

Hyderabad, Telangana State

Prevalence of Breast Cancer Subtypes According to Race and Menopausal Status in Carolina study

African American Non African American

TumorSubtype

All cases Pre menopausaln = 97

Post menopausaln = 99

Pre menopausaln = 164

Post menopausaln = 136

Triple negative 100 38 (39) 14 (14) 26 (16) 22 (16)

Her2 positive 33 9 (9) 7 (7) 9 (6) 8 (6)

Luminal A 255 35 (36) 58 (59) 83 (51) 79 (58)

Luminal B 77 9 (9) 16 (16) 30 (18) 22 (16)

unclassified 31 6 (6) 4 (4) 16 (10) 5 (4)

figures in brackets are percentage

Therapy options In differentmolecular

subtypes

IDCC with lymphocytic infiltrationAround the cell clusters.

Er negativity In the same case

Her2 3+ in plasma membrane

Estrogen receptorNuclear positivity

Progesterone positivityIn nuclei

ER negative In nuclei

Estrogen receptor Negativityin nuclei of the tumor cellshigher magnification

Her2 3+Positive membraneStaining in more than 10% of contiguous tumor cells

Her2 2+Membrane positivity In <10% of cells

Her2 1+ occasional Membrane positivity

Age Group No.of Cases Percentage

21-30 11 7

31-40 33 22

41-50 51 34

51-60 34 23

61 and Above 21 14

Age Total

Total ER+ve ER-ve

HER1+ HER2+ HER3+

HER-

ve HER1+ HER2+ HER3+

HER-

ve

21-30 11 0 0 1 2 0 1 3 4

31-40 33 1 1 7 3 2 3 13 3

41-50 51 1 2 9 4 0 3 16 16

51-60 34 0 6 6 4 1 1 9 7

61 -

above 21 0 3 4 4 0 3 1 6

Actual observation of receptor status

Her3+47%

Her2+21%

Her1+3%

Her Neg29%

Percentage of each category in ER+ve

ER+ve 58

Her3+ 27

Her2+ 12

Her1+ 2

Her Neg 17

Her 3+46%

HER 2+12%HER1+

3%

HER -ve39%

Total Percentage in ER-ve

ER-ve Total 92

Her 3+ 42

HER 2+ 11

HER1+ 3

HER -ve 36

Age Group Total cases Luminal A Luminal B Her2 Triple negative

HER 2+ER + ER -

21 - 30 11 2 1 3 4 0 131 - 40 33 4 7 13 5 1 341 - 50 51 5 9 16 16 2 351 - 60 34 4 6 9 8 6 161 and above 21 4 4 1 6 3 3Total 150 19 27 42 39 12 11

Categorization in to subtypes according to age

Age Group Total cases

Luminal A Luminal B Her2 Triple negative

unclassified

Pre menopausal

95 11 (11.57) 17 (17.89) 32 (33.68) 25 (26.31) 10 (9.5)

Postmenopausal

55 8 (14.54) 10(18.18) 10 (18.18) 14 (25.45) 13 (23.63)

Total

150 19 (12.66) 27 (18) 42 (28) 39 (26) 23 (15.33)

Categorization according to menopausal state

Study population African American population

Sub Types Pre Menopausal Post menopausal Pre menopausal Post menopausal

Triple Negative 25 (26.31) 14 (25.45) 38 (39) 14 (14)

Her 2 Positive 32 (33.68) 10 (18.18) 9 (9) 7 (7)

Luminal A 11 (11.57) 8 (14.54) 35 (36) 58 (59)

Luminal B 17 (17.89) 10(18.18) 9 (9) 16 (16)

Unclassifiable 10 (9.5) 13 (23.63) 6 (6) 4 (4)

Total 95 55 97 99

Incidence of different subtypes in study population and African American population in CBS

Study population Non African Americans

Sub Types Pre Menopausal Post menopausal Pre menopausaln = 164

Post menopausaln = 136

Triple Negative

25 (26.31) 14 (25.45) 26 (16) 22 (16)

Her 2 Positive 32 (33.68) 10 (18.18) 9 (6) 8 (6)

Luminal A 11 (11.57) 8 (14.54) 83 (51) 79 (58)

Luminal B 17 (17.89) 10(18.18) 30 (18) 22 (16)

Unclassifiable 10 (9.5) 13 (23.63) 16 (10) 5 (4)

Total 95 55 164 136

Incidence of different subtypes in study population and Non African American population in CBS

*Chandrika Rao, Jayaprakash Shetty, HL Kishan PrasadDepartment of Pathology, K S Hegde Medical Academy, Deralakatte, Mangalore, Karnataka, India

"The most important takeaway for our colleagues in breast cancer diagnosis and treatment is the potential value of molecular subtyping to personalize and improve each woman's treatment,"

Thank you all

Thankyou all